Intranasal LHRH agonist combined periodically with a progestogen for contraception

References LemayA. (1987). Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.Fertil. Steril.,48, 10–12 LemayA. (1989). Clinical appreciation of LHRH analogue formulations.Horm. Res.,32, 93–102 NilliusS.J., BergquistC. and WideL. (1978). Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue—a new approach to birth control?Contraception,17, 537–545 BergquistC., NilliusS.J. and WideL. (1979). Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.Contraception,17, 497–506 BergquistC., NilliusS.J. and WideL. (1979). Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.Lancet,1, 215–216 Schmidt-GollwitzerM., HardtW., Schmidt-GollwitzerK., von derOheM. and Nevinny-StickelJ. (1981). Influence of the LH-RH Analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?Contraception,23, 187–195 HardtW., Schmidt-GollwitzerM., von derOheM. and Nevinny-StickelJ. (1981). Der Einfluß der Dauer-medikation des LH-RH Analogons Buserelin auf die Zyklusregulation.Geburtsh. Frauenheilk.,41, 791–796 BergquistC., NilliusS.J., WideL. and LindgrenA. (1981). Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.Fertil. Steril.,36, 339–342 BerquistC., NilliusS.J. and WideL. (1982). Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.Fertil. Steril.,38, 190–193 GudmundssonJ.A., NilliusS.J. and BerquistC. (1984). Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.Contraception,30, 107–114 NilliusS.J. (1985). Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.J. Steroid. Biochem.,23, 849–854 BrennerP.F., ShoupeD. and MishellD.R.Jr (1985). Ovulation inhibition with nafarelin acetate nasal administration for six months.Contraception,32, 531–551 GudmundssonJ.A., NilliusS.J. and BerquistC. (1986). Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.Fertil. Steril.,45, 617–623 MonroeS.E., BlumenfeldZ., AndreykoJ.L., SchriockE., HenzlM.R. and JaffeR.B. (1986). Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (Nafarelin).J. Clin. Endocrinol. Metab.,63, 1334–1341 LundkvistO. and BerquistC. (1985). Morphological studies of human endometrium during continous LH-RH agonist treatment.Int. J. Fertil.,30, 65–70 GudmundssonJ.A., LjunghallS., BerquistC., WideL. and NilliusS.J. (1987). Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition.J. Clin. Endocrinol. Metab.,65, 159–163 FraserH.M., DewartP.J., SmithS.K., CowenG.M., SandowJ. and McNeillyA.S. (1989). Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.J. Clin. Endocrinol. Metab.,65, 996–1002 DewartP.J., McNeillyA.S., SmithS.K., SandowJ., HillierS.G. and FraserH.M. (1987). LHRH agonist buserelin as a post-partum contraceptive: lack of biological activity of buserelin in breast milk.Acta Endocrinol. (Copenh.),114, 185–192 HardtW., Schmidt-GollwitzerK., Nevinny-StickelJ. and Schmidt-GollwitzerM. (1982). Fortschritte in der Kontrazeptiven anwendung des LH-RH-agonisten Buserelin: diskontinuierliche Medikation mit gestagenin-duzierter Abbruchblutung.Geburtsh. Frauenheilk.,42, 874–877 LemayA., FaureN., LabrieF. and FazekasA.T.A. (1985). Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.Fertil. Steril.,43, 868–877 LemayA. and FaureN. (1986). Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.J. Clin. Endocrinol. Metab.,63, 1379–1385 LemayA., FaureN. and BastideA. (1987). Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.Fertil. Steril.,47, 60–66 LemayA., JeanC. and FaureN. (1987). Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.Fertil. Steril.,48, 775–782 GeisthovelF., JenneD., WieackerP. and BreckwoldtM. (1987). Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives.Contraception,36, 459–469 Geisthovel, F., Wieacker, P., Greif, M. and Breckwoldt, M. (1989). Buserelin and progesterone (P) in risk patients to oral contraceptives (OC). The XIII World Congress on Fertility and Sterility, Marrakesh, October 1989, p. 563 (Abstr.) Birkhäuser, M.H., Witthaus, E., Werner, I. and Huber, P. (1989). Contraception by a cyclic buserelin/gestagen-combination: result of 410 contraceptive cycles. Presented at the International Symposium entitled: ‘The present place of LHRH analogues in gynaecology’, Brussels Congress Centre, Belgium, June 9–10, 1989 SchumacherT., ZwirnerM., UnterbergH., PohlC., KellerE. and SchindlerA.E. (1984). Effects of the LHRH-analogue buserelin given discontinuously as a contraceptive on ovarian cycle and lipometabolism.Neuroendocrinol. Lett.,6, 267–272 LemayA. and Dodin DewaillyS. (1989). Long-term use of the low dose LHRH analogue combined with monthly medroxyprogesterone administration.Horm. Res.,32, 141–145 Author information Authors and Affiliations Rights and permissions About this article Cite this article Lemay, A. Intranasal LHRH agonist combined periodically with a progestogen for contraception. Adv Contracept 5, 253–262 (1989). https://doi.org/10.1007/BF01890898 Issue date: DOI: https://doi.org/10.1007/BF01890898